Partner Perspective: Patient Case Study - CONTINUOUS MICRODOSING™ TREATMENT WITH ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19mg

February 1, 2018

Article

Click here for Full Prescribing Information

OUR COLLEAGUE: Jessica D. McCluskey, MD - Atlanta, GA

“I wanted a treatment that was designed to treat patients for a longer time. When your patients ask, answer and act.”

- Dr. McCluskey

Board-certified ophthalmologist and fellowship-trained retina specialist at Thomas Eye Group, a large multispecialty ophthalmology practice

Academic affiliations:

• Medical School at the University of Mississippi – received Awards in Excellence in the fields of ophthalmology and neurosurgery

• Four-year ophthalmology residency at the University of Mississippi where she served as chief resident

• Two-year retina fellowship at the University of Texas Southwestern Medical Center

Dr. McCluskey serves as a medical reviewer for Alimera Sciences, Inc.

Reasons Dr. McCluskey chose ILUVIEN:

• Patient history of monthly injections over the course of 6 years
• Missed injections negatively impacted patient’s vision
• Interested in an alternative to monthly injections

IMPORTANT SAFETY INFORMATION

INDICATION

ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg is indicated for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure.

CONTRAINDICATIONS

• ILUVIEN is contraindicated in patients with active or suspected ocular or periocular infections including most viral disease of the cornea and conjunctiva including active epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections and fungal diseases.

• ILUVIEN is contraindicated in patients with glaucoma, who have cup to disc ratios of greater than 0.8.

• ILUVIEN is contraindicated in patients with known hypersensitivity to any components of this product.

“This patient received monthly DME injections for years and after the ILUVIEN injection, she has not had another injection in 16 months. That’s a huge success for my patient.”

- Dr. McCluskey

Above results are from a single case; results may vary.

IMPORTANT SAFETY INFORMATION (CONTINUED)

WARNINGS AND PRECAUTIONS

• Intravitreal injections, including those with ILUVIEN, have been associated with endophthalmitis, eye inflammation, increased intraocular pressure, and retinal detachments. Patients should be monitored following the intravitreal injection.

• Use of corticosteroids including ILUVIEN may produce posterior subcapsular cataracts, increased intraocular pressure and glaucoma. Use of corticosteroids may enhance the establishment of secondary ocular infections due to bacteria, fungi, or viruses. Corticosteroids are not recommended to be used in patients with a history of ocular herpes simplex because of the potential for reactivation of the viral infection.

• Patients in whom the posterior capsule of the lens is absent or has a tear are at risk of implant migration into the anterior chamber.

ADVERSE REACTIONS

• In controlled studies, the most common adverse reactions reported were cataract development (ILUVIEN 82%; sham 50%) and intraocular pressure elevation of ≥ 10 mm Hg (ILUVIEN 34%; sham 10%).

For full Prescribing Information click here:

Reference: 1. Data on file. Alimera Sciences, Inc.

ILUVIEN. (fluocinolone acetonide intravitreal implant) 0.19 mg is indicated for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure.